Skip to main content

Advertisement

Table 3 Arm B (vaccine + GM-CSF): patient profiles, clinical data, and immunological outcomes

From: The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

Pt Age Cancer Stage on enrollment # of cycles Off-study reason PFS#(ms) OS* (ms) Immune response
Proliferative assay Elispot
         Pre-vaccine Post-vaccine Pre-vaccine Post-vaccine
1B 55 Biliary NED 3 PD 2.9 8.7 + + + +
2B 33 Colon IV 3 PD 2.9 16.9 - + NA
3B 51 Colon IV 5 PPS/Lost to follow-up 9.2+ 52.6 + + - +
4B 48 Pancreatic NED 13 Completed 35.4+ 35.4 - + - -
5B 51 Colon IV 1 PD 1 1.5 ND
6B 38 Colon IV 1 Refused further Tx 0.2+ 8.3 ND
7B 60 Pancreatic IV 3 PD 4.6 21 - - NA
8B 57 Colon IV 3 PD 3.1 6.8 NA
9B 52 Colon IV 3 PD 3.3 28.3 - + + +
10B 58 Pancreatic IV 3 PD 2.9 20.9 + + - +
11B 45 Pancreatic IV 2 PD 1 7.3 ND
12B 79 Colon IV 3 PPS 12.9 42.1 - + - +
13B 43 Colon IV 3 PD 2.6 6.3 - - - +
14B 78 Colon NED 8 Left voluntarily 16.8 69 - + - +
15B 63 Colon IV 3 PD 2.8 11.6 + + - +
16B 64 Colon IV 6 PD 5.7 20.7 - + - -
17B 71 Colon IV 6 PD 5.6 25.9 - + - +
18B 58 Pancreatic IV 2 PD 2.6 3.3 ND
  1. #Progression free survival was calculated as time from the date the consent was signed until evidence of disease progression or last follow-up without progression (+). *Overall Survival was calculated as time from consent date until death or last follow-up (+). ND, not done because patient received 2 or less vaccines; NA, sample not available. Arm B (Vaccine + GM-CSF): Patient Profiles, Clinical Data, and Immunological Outcomes.
  2. Abbreviations: NED No Evidence of Disease, PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, PFS Progression Free Survival, OS Overall Survival, ms Months.